



MEDICARE FORM

Herceptin® (trastuzumab), Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk), Herzuma (trastuzumab-pkrb), Kadcyla® (ado-trastuzumab), Kanjinti (trastuzumab-anns), Ogivri (trastuzumab-dkst), Ontruzant (trastuzumab-dttb), Perjeta® (pertuzumab) and Trazimera (trastuzumab-qyyp)
Precertification Request

Page 1 of 3

(All fields must be completed and legible for Precertification Review.)

For Virginia HMO SNP:

FAX: 1-833-280-5224

PHONE: 1-855-463-0933

For other lines of business:

Please use other form.

Note: Herzuma, Ogivri, and Ontruzant are non-preferred. The preferred products are Herceptin, Herceptin Hylecta, Kanjinti, and Trazimera.

Please indicate: ☐ Start of treatment: Start date ____/____/____
☐ Continuation of therapy: Date of last treatment ____/____/____

Precertification Requested By: _____ **Phone:** _____ **Fax:** _____

A. PATIENT INFORMATION

First Name:		Last Name:	
Address:		City:	State: ZIP:
Home Phone:	Work Phone:	Cell Phone:	
DOB:	Allergies:	E-mail:	
Current Weight: _____ lbs or _____ kgs		Height: _____ inches or _____ cms	

B. INSURANCE INFORMATION

Aetna Member ID #:	Does patient have other coverage? ☐ Yes ☐ No
Group #:	If yes, provide ID#: _____ Carrier Name: _____
Insured:	Insured: _____

C. PRESCRIBER INFORMATION

First Name:	Last Name:	(Check One): ☐ M.D. ☐ D.O. ☐ N.P. ☐ P.A.			
Address:		City:	State:	ZIP:	
Phone:	Fax:	St Lic #:	NPI #:	DEA #:	UPIN:
Office Contact Name:			Phone:		

D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

Place of Administration: ☐ Self-administered ☐ Physician's Office ☐ Outpatient Infusion Center Phone: _____ Center Name: _____ ☐ Home Infusion Center Phone: _____ Agency Name: _____ Address: _____ ☐ Administration code(s) (CPT): _____	Dispensing Provider/Pharmacy: ☐ Physician's Office ☐ Retail Pharmacy ☐ Specialty Pharmacy ☐ Other _____ Name: _____ Address: _____ Phone: _____ Fax: _____ TIN: _____ PIN: _____
---	---

E. PRODUCT INFORMATION

Request is for: ☐ Herceptin (trastuzumab) ☐ Perjeta (pertuzumab) ☐ Kadcyla (ado-trastuzumab emtansine) ☐ Ogivri (trastuzumab-dkst)
☐ Ontruzant (trastuzumab-dttb) ☐ Herzuma (trastuzumab-pkrb) ☐ Herceptin Hylecta (trastuzumab and hyaluronidase-oysk)
☐ Kanjinti (trastuzumab-anns) ☐ Trazimera (trastuzumab-qyyp)

Dose: _____ **Frequency:** _____ **HCPCS Code:** _____

F. DIAGNOSIS INFORMATION – Please indicate primary ICD Code and specify any other where applicable.

Primary ICD Code: _____ **Secondary ICD Code:** _____ **Other ICD Code:** _____

G. CLINICAL INFORMATION – Required clinical information must be completed in its entirety for all precertification requests.

For All Requests (clinical documentation required):

☐ Yes ☐ No Does the patient have HER2 protein overexpression documented by one of the following?

Check all that apply:

☐ Immunohistochemistry (IHC) Assay level of 3+

→ Results _____ Date of Test: ____/____/____

☐ Positive Fluorescent in situ hybridization (FISH) HER2 gene copy of greater than 6 signals/nucleus

→ Results _____ Date of Test: ____/____/____

☐ Positive Fluorescent in situ hybridization (FISH) HER2 gene/ chromosome 17 ratio greater than or equal to 2.0

→ Results _____ Date of Test: ____/____/____

Note: Herzuma, Ogivri, and Ontruzant are non-preferred. The preferred products are Herceptin, Herceptin Hylecta, Kanjinti, and Trazimera.

Preferred products may vary based on indication.

☐ Yes ☐ No Has the patient had prior therapy with Herzuma, Ogivri, or Ontruzant within the last 365 days?

☐ Yes ☐ No Has the patient had a trial, intolerance, or contraindication to Herceptin, Herceptin Hylecta, Kanjinti, or Trazimera?

Continued on next page



MEDICARE FORM

Herceptin® (trastuzumab), Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk), Herxuma (trastuzumab-pkrb), Kadcyla® (ado-trastuzumab), Kanjinti (trastuzumab-anns), Ogivri (trastuzumab-dkst), Ontruzant (trastuzumab-dttb), Perjeta® (pertuzumab) and Trazimera (trastuzumab-qyyp)
Precertification Request

Page 2 of 3

(All fields must be completed and legible for Precertification Review.)

For Virginia HMO SNP:

FAX: 1-833-280-5224

PHONE: 1-855-463-0933

For other lines of business:

Please use other form.

Note: Herxuma, Ogivri, and Ontruzant are non-preferred. The preferred products are Herceptin, Herceptin Hylecta, Kanjinti, and Trazimera.

Patient First Name	Patient Last Name	Patient Phone	Patient DOB
--------------------	-------------------	---------------	-------------

G. CLINICAL INFORMATION (continued) – Required clinical information must be completed in its entirety for all precertification requests.

Please explain if there are any other medical reason(s) that the patient cannot use Herceptin, Herceptin Hylecta, Kanjinti, or Trazimera.

HERCEPTIN (trastuzumab):

☐ Esophageal adenocarcinoma ☐ Gastric adenocarcinoma ☐ Esophageal-gastric junction adenocarcinoma

☐ Yes ☐ No Will Herceptin (trastuzumab) be used as palliative therapy?

☐ Yes ☐ No Will Herceptin (trastuzumab) be used in combination with systemic chemotherapy?

→ Please provide the name of the systemic chemotherapy: _____

Endometrial carcinoma

☐ Yes ☐ No Does the patient have advanced (stage III/IV) disease?

☐ Yes ☐ No Does the patient have a documented diagnosis of uterine serous carcinoma?

☐ Yes ☐ No Does the patient have recurrent disease?

☐ Yes ☐ No Will Herceptin (trastuzumab) be used in combination with carboplatin and paclitaxel?

Salivary gland tumors

☐ Yes ☐ No Does the patient have recurrent disease with distant metastases?

Please indicate how Herceptin (trastuzumab) will be used: ☐ single agent ☐ Other: Please explain: _____

☐ in combination with systemic chemotherapy: Name of systemic chemotherapy: _____

HER2 positive breast cancer

☐ Yes ☐ No Does the patient have recurrent, metastatic, stage IV disease or leptomeningeal metastases from breast cancer (as intracerebrospinal fluid treatment)? ☐ recurrent disease ☐ metastatic disease ☐ stage IV disease

☐ leptomeningeal metastases from breast cancer (as intracerebrospinal fluid treatment)

→ ☐ Yes ☐ No Will Herceptin (trastuzumab) be used as pre-operative (neoadjuvant) systemic therapy?

→ Please select in which of the following settings Herceptin (trastuzumab) will be used:

☐ Node-positive disease likely to become node-negative with pre-operative systemic therapy

☐ Locally advanced disease ☐ Individuals who fulfill criteria for breast-conserving surgery except for tumor size

☐ None of the above

☐ Yes ☐ No Will Herceptin (trastuzumab) be used as adjuvant therapy?

☐ Yes ☐ No Will Herceptin (trastuzumab) be used as part of a complete treatment regimen?

HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk):

HER2 positive breast cancer

Please select which of the following applies to the patient's disease stage:

☐ Early stage HER2-overexpressing breast cancer

→ ☐ Yes ☐ No Will Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) be used as adjuvant therapy?

☐ Metastatic HER2-overexpressing breast cancer

☐ Other

PERJETA (pertuzumab) with HERCEPTIN (trastuzumab):

(please ensure dosing and instructions for both drugs are documented in section E) HER2 positive breast cancer

Please select which type of treatment Perjeta (pertuzumab) and Herceptin (trastuzumab) is being used for:

☐ Adjuvant therapy

→ ☐ Yes ☐ No Is the patient's disease node-positive or at high-risk for recurrence?

→ Please select: ☐ Node-positive ☐ At high-risk for recurrence ☐ Other: _____

☐ Preoperative (neoadjuvant) therapy

→ Please select in which of the following settings Perjeta (pertuzumab) with Herceptin (trastuzumab) will be used:

☐ Node-positive disease likely to become node-negative with pre-operative systemic therapy

☐ Individuals who desire breast preservation and fulfill criteria for breast-conserving surgery except for tumor size

☐ Locally advanced disease ☐ None of the above

☐ Other

→ Please indicate which applies to the patient's disease: ☐ Recurrent disease ☐ Metastatic disease

☐ Yes ☐ No Does the patient have symptomatic visceral disease or visceral crisis?

→ Please specify: ☐ Symptomatic visceral disease ☐ Visceral crisis

Continued on next page



MEDICARE FORM

Herceptin® (trastuzumab), Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk), Herzuma (trastuzumab-pkrb), Kadcyła® (ado-trastuzumab), Kanjinti (trastuzumab-anns), Ogivri (trastuzumab-dkst), Ontruzant (trastuzumab-dttb), Perjeta® (pertuzumab) and Trazimera (trastuzumab-qyyp)
Precertification Request

Page 3 of 3

(All fields must be completed and legible for Precertification Review.)

For Virginia HMO SNP:

FAX: 1-833-280-5224

PHONE: 1-855-463-0933

For other lines of business:

Please use other form.

Note: Herzuma, Ogivri, and Ontruzant are non-preferred. The preferred products are Herceptin, Herceptin Hylecta, Kanjinti, and Trazimera.

Patient First Name	Patient Last Name	Patient Phone	Patient DOB
--------------------	-------------------	---------------	-------------

G. CLINICAL INFORMATION (continued) – Required clinical information must be completed in its entirety for all precertification requests.

KADCYLA (ado-trastuzumab emtansine):

☐ Yes ☐ No Does the patient have a documented diagnosis of HER2-positive non-small cell lung cancer?

☐ Yes ☐ No Is the patient being treated for HER2-positive recurrent or metastatic breast cancer?

☐ Yes ☐ No Will Kadcyła (ado-trastuzumab emtansine) be used as adjuvant systemic therapy?

☐ Yes ☐ No Has the patient received neoadjuvant therapy containing a taxane (with or without anthracycline) and trastuzumab?

Please provide the date range of use: ____ / ____ / ____ to ____ / ____ / ____

☐ Yes ☐ No Does the patient have a residual disease after receiving neoadjuvant therapy?

Please indicate which applies: ☐ recurrent breast cancer ☐ metastatic breast cancer

☐ Yes ☐ No Does the patient have symptomatic visceral disease or visceral crisis?

Please indicate the type of breast cancer: ☐ Hormone receptor- negative ☐ Hormone receptor-positive ☐ Unknown ☐ Other

☐ Yes ☐ No Is the breast cancer refractory to endocrine therapy?

Please select which of the following endocrine therapy the patient is refractory to:

☐ Nonsteroidal aromatase inhibitors (anastrozole and letrozole)

☐ Steroidal aromatase inhibitors (exemestane)

☐ Estrogen receptor (ER) antagonists (tamoxifen or toremifene)

☐ ER down-regulators (fulvestrant) ☐ High-dose estrogen (ethinyl estradiol)

☐ Androgens (fluoxymesterone) ☐ Other: Please explain: _____

☐ Yes ☐ No Will Kadcyła (ado-trastuzumab emtansine) be used as a single agent?

☐ Yes ☐ No Will Kadcyła (ado-trastuzumab emtansine) be used concomitantly with Herceptin (trastuzumab), Tykerb (lapatinib), or Perjeta (pertuzumab)?

For Continuation Requests (clinical documentation required):

☐ Yes ☐ No Has the patient experienced disease progression or unacceptable toxicity while on HER2 therapy?

☐ Disease progression ☐ Unacceptable toxicity

HERCEPTIN (trastuzumab):

For HER2-positive breast cancer only:

☐ Yes ☐ No Is there clinical evidence of distant metastatic disease?

Please provide initial start date: ____ / ____ / ____

HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk):

☐ Yes ☐ No Will Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) be used in adjuvant settings?

Please provide the initial start date: ____ / ____ / ____

PERJETA (pertuzumab) with HERCEPTIN (trastuzumab):

☐ Yes ☐ No Is there clinical evidence of distant metastatic disease?

Please provide initial start date: ____ / ____ / ____

KADCYLA (ado-trastuzumab emtansine):

☐ Yes ☐ No Is Kadcyła (ado-trastuzumab emtansine) being used concomitantly with Herceptin (trastuzumab), Tykerb (lapatinib), or Perjeta (pertuzumab)?

☐ Yes ☐ No Is there clinical evidence of metastatic disease?

Please provide initial start date: ____ / ____ / ____

H. ACKNOWLEDGEMENT

Request Completed By (Signature Required): _____ **Date:** ____ / ____ / ____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.